EMMPRIN (CD147)

Roman Nawroth(TUM Klinikum), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie), Peter J. Wild(Goethe University Frankfurt), Amely Hartmann(Institut für Psychogerontologie), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), J. E. Gschwend(TUM Klinikum)
Der Pathologe
July 26, 2010
10.1007/s00292-010-1328-8
Cited by 3

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
|Nature Methods|2014|2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k